Bonus BioGroup is a
product-focused biotechnology company applying proprietary,
pioneer technology for supplying bone regeneration tissues.
Bonus BioGroup is developing cell therapy products based on
autologous and allogeneic bone implants that will enable
efficient bone transplant and provide cellular-based bone
replacement prosthetics for repairing bone lesions. On April 29,
2012, Bonus BioGroup Ltd (TASE: BONS) (Previous name: Oceania
advanced industries Ltd), accomplished a share purchase of full
share capital of BonusTherapeutic Ltd.
Bonus BioGroup is targeting multi billion worldwide market for
the treatment of major disorders such as bone and cartilage
related arthritis, osteoporosis, and various types of bones and
joint trauma (hip fractures, knee injuries, etc). This market
experiences over 2 million bone graft procedures annually.
Bonus BioGroup products shall replace today's autologous bone
grafting procedure. Autologous bone grafting is the current gold
standard in the bone reconstitution field accounting for most
bone reconstructions performed. However, the current procedure
has severemajor handicaps: in many cases the amount of
autologous bone needed for the bone graft is not available for
effective treatments; the existing procedure incurs donor
morbidity and reduced graft strength and is associated with
chronic pain, discomfort, and mobility problems.Moreover, the
autologous bonegrafts cannot be accurately shaped to fit the
missing bone, damaging the healing process, and leaving
unaesthetic cavities in the treated patients.
Those handicaps create an unparalleled and urgent need for a
more effective solution in this a multi-billion dollar market.
Bonus BioGroup technology provides a breakthrough solution to the
key biological problem that has hindered the wider use of bone
grafts, and gives Bonus BioGroup its leading competitive edge.
Bonus BioGroup has developed a method to grow unique 3D
high-density bone graft based on multi-cells cultures, allowing
the bone graft to be accepted by the patents better and faster
in comparison to any other alternative.
Cultured from the patient's own cells, this bone regenerative
methodology is a powerful tool for treating avariety of bone and
joints diseases without running the risk of tissue rejections
and surgery failures.
In addition, the technology developed by Bonus BioGroup
scientific team, make it possible to produce the matched bone
tissue in the precise pre-designed needed architecture. This
leads to bone transplant available on demand, fits like a
tailored suit, safer, less expensive, and therefore provides a
better outcome than by any other solution available to date.
Another unique aspect of the company’s technology is the use of
its proprietary bioreactor technology enabling the developed
cell-matrix hybrid bone culturing technology to be used in most
bone repair applications.
Bonus BioGroup experienced scientific team has attained
significant knowhow solving the major development issues as cell
expansion and differentiation methodology and the ability to
grow high density physiological like tissues. This unique
knowledge gives the company the ability to produce bone grafts
on demand and at the needed shape for regenerative medicine.
Bonus BioGroup intends to develop its products, perform clinical
trials, and gain regulatory authorities approvals for the use of
its bone grafts. The designed bone grafts will address a very
substantial portion of the regeneration medicine market, and
thus represent a highly attractive market opportunity.